Switching Antipsychotics May Not Be Best Option, New CATIE Analysis Finds
Executive Summary
Ongoing analyses of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) continue to support a benefit for Lilly's Zyprexa over other antipsychotic medications, with the latest trial results showing that Zyprexa is the only atypical where patients did better by remaining on the drug
You may also be interested in...
CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals
The first-generation antipsychotic perphenazine (Schering-Plough's Trilafon and generics) is less costly and just as effective in treating schizophrenia as second-generation antipsychotics, according to an economic analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program
Clozaril Superior In Phase Two Of CATIE, But Side Effects Remain A Challenge
The superiority of Novartis' Clozaril over second-generation antipsychotics in the second phase of the National Institute of Mental Health's CATIE trial suggests the need to manage the serious side effects of clozapine therapy while expanding its use, study authors argue
CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM
Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study